Pheochromocytoma
📧 Sign up to get email alerts when something new happens for Pheochromocytoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery [Phase 2]
Phase 2 clinical trial evaluating lenvatinib for metastatic or advanced pheochromocytoma or paraganglioma that cannot be surgically removed;…
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer [Phase 2]
A Phase II trial of the DNA methyltransferase inhibitor guadecitabine (SGI-110) in children and adults with wild-type GIST, paraganglioma, p…
-
FDA approval · 2020-10-27FDA Approved: PHENOXYBENZAMINE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved phenoxybenzamine hydrochloride under an original ANDA for Amneal Pharmaceuticals NY LLC.
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma [Phase 2]
Phase II study evaluating axitinib (AG-013736) targeting VEGF pathway in metastatic/recurrent/unresectable pheochromocytoma and paragangliom…
-
FDA approval · 2020-07-24FDA Approved: METYROSINE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic metyrosine (METYROSINE) under Original Application ANDA213734.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-04-14Clinical Trial Update: Dovitinib in Neuroendocrine Tumors [Phase 2]
Phase 2 trial of dovitinib in neuroendocrine tumors (paraganglioma and pheochromocytoma) completed.
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma [Phase 3]
A Phase 3 clinical trial evaluating meta-iodobenzylguanidine (123I mIBG) scintigraphy in patients being evaluated for pheochromocytoma or ne…
-
FDA approval · 2019-03-22FDA Approved: PROPRANOLOL HYDROCHLORIDE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental application for propranolol hydrochloride (generic propranolol HCl).
-
CLINICAL_TRIALS approval · 2019-01-30Clinical Trial Update: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Marketing approval for Ultratrace iobenguane I-131 has been granted for malignant relapsed/refractory pheochromocytoma and paraganglioma, pe…
-
CLINICAL_TRIALS trial_result · 2018-10-05Clinical Trial Update: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma [Phase 2]
Phase 2 study evaluating ultratrace Iobenguane I-131 in malignant relapsed/refractory pheochromocytoma and paraganglioma; results posted in …
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors [Phase 2]
Phase II clinical trial evaluating 131I-Metaiodobenzylguanidine (MIBG) for metastatic or unresectable pheochromocytoma and related tumors ha…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: 131MIBG to Treat Malignant Pheochromocytoma [Phase 2]
A Phase 2 clinical trial investigating iobenguane I-131 (131I-MIBG) for malignant pheochromocytoma has completed.
-
CLINICAL_TRIALS research · 2017-05-18Clinical Trial Update: Surgeon-Anesthesiologist Collaboration
The update describes a clinical trial exploring collaboration between surgeons and anesthesiologists for pheochromocytoma. The current statu…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study [NA]
This completed trial evaluated the efficacy and safety of posterior retroperitoneoscopic adrenalectomy in adrenal diseases, including pheoch…
-
CLINICAL_TRIALS trial_result · 2016-07-21Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma [Phase 2]
Phase 2 trial of pazopanib hydrochloride in advanced or progressive malignant pheochromocytoma or paraganglioma was terminated with results …
-
CLINICAL_TRIALS trial_result · 2016-06-21Clinical Trial Update: Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors [Phase 1]
This Phase 1 trial update assesses the safety and feasibility of radiolabeled octreotide in pediatric patients with advanced or refractory s…
-
CLINICAL_TRIALS trial_result · 2016-06-13Clinical Trial Update: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors [Phase 1]
A Phase 1 trial evaluating the combination of temsirolimus and vinorelbine ditartrate in adults with unresectable or metastatic solid tumors…
-
CLINICAL_TRIALS trial_result · 2016-04-20Clinical Trial Update: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma [Phase 1, Phase 2]
Phase 1/2 study of iobenguane I-131 (MIBG) in patients with malignant pheochromocytoma or paraganglioma completed; results were posted in 20…
-
CLINICAL_TRIALS withdrawal · 2015-12-21Clinical Trial Update: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma [Phase 1]
The Phase I trial of vandetanib in combination with 131I-mIBG for advanced pheochromocytoma and paraganglioma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-07-23Clinical Trial Update: Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers [NA]
This completed clinical trial evaluated screening methods to detect tumors in SDH-positive carriers, addressing hereditary paraganglioma and…
-
CLINICAL_TRIALS trial_result · 2015-05-20Clinical Trial Update: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid [Phase 2]
A Phase 2 trial of RAD001 (everolimus) for pheochromocytoma, extra-adrenal paraganglioma, and non-functioning carcinoid has completed.
-
FDA approval · 2014-07-15FDA Approved: DEMSER — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for Demser (metyrosine) submitted by Bausch Health US, LLC. The approval updates the drug's labe…
-
CLINICAL_TRIALS trial_result · 2014-02-25Clinical Trial Update: Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot [NA]
A completed pilot study assessing the feasibility of Iodine-123 IBZM scintigraphy as a diagnostic imaging tool in patients with pheochromocy…
-
CLINICAL_TRIALS trial_result · 2014-02-13Clinical Trial Update: Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
This clinical trial evaluated non-invasive methods for assessing fluid status and cardiac output during the operative treatment of pheochrom…
-
FDA approval · 2013-11-08FDA Approved: DEMSER — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for DEMSER (metyrosine) filed by Bausch Health US, LLC.